Medicare's new GLP-1 coverage: who it's actually for

TL;DR: Medicare's GLP-1 Bridge went live July 1: eligible Part D beneficiaries can now fill Wegovy, Zepbound's KwikPen, or the Foundayo pill for $50 a month through 2027 — Medicare's first-ever coverage for a drug prescribed specifically for weight loss. Eligibility runs on BMI and health history, not just a prescription. The same summer, Massachusetts and California are narrowing GLP-1 coverage.

What changed July 1

For 20 years — the entire life of Medicare Part D — the program has been barred by law from paying for a drug prescribed specifically for weight loss. On July 1, that changed, temporarily. The Medicare GLP-1 Bridge, a short-term demonstration run by the Centers for Medicare & Medicaid Services, lets eligible Part D beneficiaries fill a covered GLP-1 prescription for a flat $50 a month — the same price regardless of dose or income, and it doesn't count toward the plan's deductible or annual out-of-pocket cap.

CMS originally built the Bridge to run six months, into the end of 2026. In April, after Part D insurers hesitated to commit to a longer follow-on program, CMS extended it instead — so the Bridge now runs through December 31, 2027, per CMS's own program page. What happens after that is genuinely unresolved.

Who it actually covers

Medicare's own eligibility sheet lists four requirements, and a beneficiary has to clear all of them. You need active Part D drug coverage (Original Medicare alone doesn't qualify you, and neither do certain plan types like PACE). You can't already be getting a GLP-1 through that Part D plan for something else. You can't have type 2 diabetes, moderate-to-severe sleep apnea, or fatty liver disease — those may already route you to coverage through your regular plan instead. And you need to be 18 or older with a BMI of 35 or higher on its own, a BMI of 30 or higher plus certain heart, blood pressure, or kidney conditions, or a BMI of 27 or higher plus prediabetes or a history of heart attack, stroke, or blocked arteries.

That's the real shape of it. The only way to know where you land is to check with Medicare or your Part D plan directly — not to guess from a news article.

The catch

Three brand names are covered: Foundayo (the tablet), Wegovy (injection or tablet), and Zepbound — but only the KwikPen. The single-dose Zepbound pen and vials aren't included. Neither are Ozempic or Mounjaro, two of the most familiar names in the category — both carry other approved uses, not a weight-loss indication, so they sit outside the Bridge's rules entirely. And if you receive Medicare's Extra Help low-income subsidy, it doesn't apply here: you pay the full $50 regardless of income.

The two-direction split

The same summer Medicare opened this door, two of the largest state Medicaid programs are closing theirs. Massachusetts' MassHealth stopped covering Wegovy and Zepbound for weight loss as of July 3 — the drugs remain covered for members being treated for cardiovascular risk, sleep apnea, or related conditions, just not for weight loss on its own. California's Medi-Cal Rx made the same call for its own members back on January 1, citing budget pressure. As of early 2026, only 13 states' Medicaid programs covered GLP-1s for weight loss at all, down from 16 the year before, according to health policy research group KFF. Same class of medications, same summer, opposite directions — federal coverage widening as state budgets pull back.

What it means for the community

None of this changes what actually keeps weight off. Coverage decides whether you can start or keep filling a prescription — it doesn't decide what happens the day the routine around it gets hard. Whether you're newly Bridge-eligible or watching a state program close a door you'd been counting on, that part of the job looks the same either way, and it was never going to be handled by a payer.

Key Takeaways

• Medicare's GLP-1 Bridge began July 1 — the first time in Part D's 20-year history that the program has covered a drug prescribed specifically for weight loss.
• Originally planned as a six-month pilot, CMS extended the Bridge in April to run through December 31, 2027, after Part D insurers hesitated on a longer-term follow-on program.
• Covered: Foundayo (tablet), Wegovy (injection or tablet), and Zepbound's KwikPen only — not the Zepbound vial or pen, and not Ozempic or Mounjaro.
• Eligibility requires active Part D coverage plus a BMI/health-condition threshold (35+ alone; 30+ with certain heart, blood pressure, or kidney conditions; 27+ with prediabetes or a cardiovascular history) — confirm your own status with Medicare or your plan, not a headline.
• The $50 copay doesn't count toward your deductible or out-of-pocket cap, and Extra Help's low-income subsidy doesn't reduce it any further.
• The same summer, Massachusetts' MassHealth (effective July 3) and California's Medi-Cal (since January 1) narrowed their own GLP-1 weight-loss coverage; only 13 states covered it at all under Medicaid as of early 2026, down from 16 the year before.

We covered this program in detail back in May, before it launched — this is the "it's actually live now" update. If a daily pill instead of a weekly shot is new territory for you, we broke down what changed when Foundayo and oral Wegovy both scaled up this year. And if you're trying to picture what happens after a coverage window like this one closes, the honest persistence numbers are worth a look.

Want to see what $50 a month actually does to your annual math versus what you're paying now? Gila's cost calculator runs that comparison in about a minute.

We track policy changes like this one as they actually happen, not as they get simplified — subscribe to the newsletter for the next update.

Gila is in its free pilot right now. Sign up for the free pilot to bring some structure to whatever comes next, coverage or not.

This article covers a Medicare and Medicaid policy change — not medical or insurance advice. Eligibility, formulary, and prior-authorization decisions belong to your prescriber and your Part D or Medicaid plan.

Sources:

• Centers for Medicare & Medicaid Services. "Medicare GLP-1 Bridge." https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge
• Centers for Medicare & Medicaid Services. "Coming Soon: CMS to Provide $50 Monthly Access to GLP-1 Medications for Medicare Beneficiaries." Press release. https://www.cms.gov/newsroom/press-releases/coming-soon-cms-provide-50-monthly-access-glp-1-medications-medicare-beneficiaries
• Medicare.gov. "Medicare GLP-1 Bridge: GLP-1 Drugs for $50 a Month." Fact sheet, CMS Product No. 12234, June 2026. https://www.medicare.gov/publications/12234-medicare-glp-1-bridge-glp-1-drugs-for-50-a-month.pdf
• Medicare.gov. "Weight loss drugs." https://www.medicare.gov/coverage/weight-loss-drugs
• Commonwealth of Massachusetts, MassHealth. "Pharmacy Facts #271: MassHealth Changes to Management of Anti-Obesity Medications" (corrected). March 12, 2026. https://www.mass.gov/doc/pharmacy-facts-271-march-12-2026-corrected-0/download
• California Department of Health Care Services, Medi-Cal Rx. "State Budget Updates." https://medi-calrx.dhcs.ca.gov/member/state-budget-updates/
• KFF. "What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid and the Medicare GLP-1 Bridge." Meredith Freed, Juliette Cubanski, Elizabeth Williams. Updated May 11, 2026. https://www.kff.org/medicare/what-to-know-about-the-balance-model-for-glp-1s-in-medicare-and-medicaid/